Effect of Curcumin on Liver enzymes and Liver T2*MRI in patients with Thalassemia.
Phase 3
- Conditions
- Iron Overload in Beta Thalassaemia Major and Intermedia patients.Thalassemia
- Registration Number
- IRCT20200807048328N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Age over 5 years old.
Patients diagnosed with Thalassemia major and intermedia.
Having conscious satisfaction.
Exclusion Criteria
Pregnancy.
History of liver disease.
Consumption of drugs affecting liver metabolism and liver enzymes and ferritin levels.
History of turmeric allergy.
Having bleeding disease.
Taking anticoagulants.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Aspartate aminotransferase. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Alanine transaminase. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Alkaline phosphatase. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Total bilirubin. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Direct bilirubin. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;Serum Ferritin. Timepoint: At the beginning of the study and every month for up to 6 months. Method of measurement: Patient blood sample.;T2*-weighted imaging. Timepoint: At the beginning of the study and 6 months later. Method of measurement: Magnetic resonanse imaging machine.
- Secondary Outcome Measures
Name Time Method